| Literature DB >> 17602874 |
S Goldacker1, R Draeger, K Warnatz, D Huzly, U Salzer, J Thiel, H Eibel, M Schlesier, H H Peter.
Abstract
Active vaccination of CVID patients with standard vaccines has rarely been studied in depth although some patients have been shown to develop transient vaccine-specific immunity. We addressed the question whether these patients can be identified by functional classification of their B cell subsets in vitro. Twenty-one CVID patients receiving regular IgG substitution were immunized with anti-peptide and anti-polysaccharide vaccines. Humoral vaccination responses were compared to the numbers of circulating memory B cells, CD21(low) B cells and the capacity to produce antibodies in vitro. Our findings allow four conclusions: (1) positive vaccination responses are not contradictory to the diagnosis of CVID; they occurred against polypeptide vaccines in 23% and against polysaccharide antigens in 18% of all vaccinations. (2) Class-switched antibody responses occur preferentially in patients of CVID group II. (3) A normal percentage of IgM memory B cells is necessary but not sufficient for a vaccination response to polysaccharide antigens. (4) Active vaccination in addition to IgG replacement therapy should be performed in patients of CVID type II - especially in case of vaccines for which passive protection cannot be guaranteed.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17602874 DOI: 10.1016/j.clim.2007.04.011
Source DB: PubMed Journal: Clin Immunol ISSN: 1521-6616 Impact factor: 3.969